← Back to Patent Explorer
US5013540A Expired / Lapsed US ⏱️ 0.0 years remaining

Using NMDA receptor antagonists to reduce damage due to laser treatment

Assignee: The University of Texas System
•
Filing: 1989-11-30
•
Granted: 1991-05-07
•
Expires: 2009-11-30
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method is disclosed for preventing the spread of damage in neuronal tissue that has been selectively burned by surgical laser treatment. Administration of an NMDA receptor blocker, such as dextrorphan, in conjunction with the laser treatment permits the site of the laser burn to be confined more precisely to the desired area, and prevents the spread of damage to surrounding tissue that would normally occur in the days after the laser treatment.

Inventors

  • 👤 Dianna A. Redburn

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 16:50
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 42 words
A method of reducing the damaging effects of laser treatment on neuronal tissue, including the step of administering to a living subject an effective amount of a NMDA receptor blocker compound in conjunction with laser treatment of neuronal tissue in that subject.
Claim 2
Independent Claim 42 words
A method of reducing the damaging effects of laser treatment on neuronal tissue, including the step of administering to a living subject an effective amount of a NMDA receptor blocker compound in conjunction with laser treatment of neuronal tissue in that subject.
Claim 3
Dependent Claim 15 words
The method of claim 1, where the NMDA receptor blocker compound is an opioid compound.
Claim 4
Dependent Claim 24 words
The method of claim 1, where the NMDA receptor blocker compound is selected from the group consisting of dextrorphan and pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim 21 words
The method of claim 1, where the NMDA receptor blocker compound is administered to the subject prior to the laser treatment.
Claim 6
Dependent Claim 22 words
The method of claim 1, where the NMDA receptor blocker compound is administered to the subject approximately concurrently with the laser treatment.
Claim 7
Dependent Claim 26 words
The method of claim 1, where the NMDA receptor blocker compound is administered to the subject both prior to and approximately concurrently with the laser treatment.
Claim 8
Independent Claim 42 words
A method of reducing the damaging effects of laser treatment on retinal tissue, including the step of administering to a living subject an effective amount of an NMDA receptor blocker compound in conjunction with laser treatment of retinal tissue in that subject.
Claim 9
Independent Claim 42 words
A method of reducing the damaging effects of laser treatment on retinal tissue, including the step of administering to a living subject an effective amount of an NMDA receptor blocker compound in conjunction with laser treatment of retinal tissue in that subject.
Claim 10
Dependent Claim 15 words
The method of claim 7, where the NMDA receptor blocker compound is an opioid compound.
Claim 11
Dependent Claim 21 words
The method of claim 7, where the NMDA receptor blocker compound is administered to the subject prior to the laser treatment.
Claim 12
Dependent Claim 22 words
The method of claim 7, where the NMDA receptor blocker compound is administered to the subject approximately concurrently with the laser treatment.
Claim 13
Dependent Claim 25 words
The method of claim 7, where the NMDA receptor blocker is administered to the subject both prior to and approximately concurrently with the laser treatment.
Claim 14
Dependent Claim 24 words
The method of claim 7, where the NMDA receptor blocker compound is selected from the group consisting of dextrorphan and pharmaceutically acceptable salts thereof.

References Cited (Backward Citations)

US4806543A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-05-06 1994-11-05 1995-05-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-05-06 1998-11-05 1999-05-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-05-06 2002-11-05 2003-05-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag